A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT ID: NCT04302324

Last Updated: 2025-10-01

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-28
• Study Completion Date: 2027-12-28

Brief Summary

This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.

Conditions

Multiple Myeloma; Refractory Multiple Myeloma; Relapse Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

daratumumab/clarithromycin/pomalidomide/dexamethasone

Induction Phase: 8 cycles (cycle length of 28 days)

• Daratumumab SC:

1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8

• Clarithromycin

500mg PO BID until VGPR or 8 cycles, whichever occurs first

• Pomalidomide 4mg PO on Days 1-21
• Dexamethasone 20mg IV as pre-medication on Day 1, 8 40mg PO on the day after daratumumab for Cycle 1 Days 15 and 22 40mg PO pre-daratumumab weekly for Cycle 2-6 20mg PO pre-daratumumab weekly for Cycle 7-8

Maintenance Phase (Cycle 9+): Up to 24 cycles (cycle length of 28 days)

• Daratumumab 1800 mg SC on Day 1
• Pomalidomide 4mg PO on Day 1-21
• Dexamethasone 20mg PO pre-daratumumab weekly for Cycles 9 and beyond

Group Type: EXPERIMENTAL

Daratumumab SC

Intervention Type: DRUG

Given as 1800mg via injection

Clarithromycin

Intervention Type: DRUG

Given as 500mg oral capsule

Pomalidomide

Intervention Type: DRUG

Given as 4mg oral capsule

Dexamethasone

Intervention Type: DRUG

Given as 20mg IV and 20mg or 40mg oral tablets

Interventions

Daratumumab SC

Given as 1800mg via injection

Intervention Type: DRUG

Clarithromycin

Given as 500mg oral capsule

Intervention Type: DRUG

Pomalidomide

Given as 4mg oral capsule

Intervention Type: DRUG

Dexamethasone

Given as 20mg IV and 20mg or 40mg oral tablets

Intervention Type: DRUG

Other Intervention Names

Faspro

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed Multiple Myeloma
• Relapsed and/or refractory myeloma defined as follows: Relapse or progressive disease after at least one previous line of therapy which must include prior daratumumab. At least 8 doses of daratumumab in a previous line must be administered either as monotherapy or in combination with a daratumumab-free interval of ≥3 months AND patient may be daratumumab refractory defined as less than a partial remission (PR) achieved on prior daratumumab-based therapy or have exhibited progression within 60 days of receiving daratumumab. If previous therapy was autologous stem cell transplant (SCT), over 3 months must have elapsed after SCT.
• Measurable disease as defined by > 0.5 g/dL serum monoclonal protein, >0.1 g/dL serum free light chains, >0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s).
• Females of childbearing potential(FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours of prescribing pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Able to take aspirin daily
• Life expectancy must be greater than 3 months.
• Be able to voluntarily sign and understand written informed consent.
• Absolute neutrophil count (ANC) ≥750 cells/mm3 (.75 x 109/L)
• Platelets count ≥ 50,000/mm3 (50 x 109/L)
• Serum SGOT/AST ≤ 2.0 x upper limits of normal
• Serum SGPT/ALT <3.0 x upper limits of normal
• Serum creatinine ≤ 2.5 x upper limits of normal
• Serum total bilirubin ≤ 1.5 x upper limits of normal (Total bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
• All participants must be registered into the mandatory POMALYST REMS™ program and be willing and able to comply with the requirements of the POMALYST REMS™ program.

Exclusion Criteria

• Prior exposure to non-daratumumab anti-CD38 monoclonal antibodies or pomalidomide. Prior pomalidomide exposure in 1 or more previous lines of therapy allowed if partial remission (PR) or better achieved. No disease progression may have occurred within 60 days of receiving pomalidomide.
• New York Heart Association (NYHA) Class III or IV heart failure, unstable cardiac arrhythmia, or unstable angina
• Myocardial infarction within the past 6 months
• Severe obstructive airway disease
• Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment
• Female patients who are lactating or have a positive serum pregnancy test during the screening period
• Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy
• Major surgery within 14 days before enrollment
• Radiotherapy within 14 days before enrollment (if area involved is small than within 7 days)
• Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
• Seropositive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
• Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
• Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
• Patient has greater than Grade 3 peripheral neuropathy, or Grade 2 pain
• Participation in other clinical trials within 30 days
• History of thromboembolic event within the past 6 months prior to enrollment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Scientific Affairs, LLC

INDUSTRY

Sponsor Role: collaborator

Weill Medical College of Cornell University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cara Rosenbaum, MD

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Locations

Weill Cornell Medicine - Multiple Myeloma Center

New York, New York, United States

Countries

United States

Other Identifiers

19-12021155

Identifier Type: -

Identifier Source: org_study_id